Search
Azficel-T
go.drugbank.com/drugs/DB11051ApprovedWithdrawnAzficel-T is marketed in the US as Laviv for intradermal injection. … Dermal fibroblasts are collected from the post-auricular biopsy tissue and aseptically expanded using standard tissue-culture procedures until sufficient cells for three doses are obtained [FDA Label].
Pixantrone
go.drugbank.com/drugs/DB06193ApprovedWithdrawnPixantrone was designed to treat relapsed or refractory aggressive non-Hodgkin's lymphoma(NHL) in patients who have failed two prior lines of therapy. [2] For patients suffering from NHL, first line therapies … Patients refractory to treatment, or those who relapse, are discouraged from further anthracycline use due to cumulative cardiotoxicity.
Sulfasalazine
go.drugbank.com/drugs/DB00795ApprovedInvestigational[A255582] Sulfasalazine fell out of favor as the drug of choice for RA due to poorly designed clinical trials in 1950 but regained interest from the clinical community in the late 1970. … [A255582] Although sulfasalazine is only approved by the FDA for ulcerative colitis, research have shown that sulfasalazine is also beneficial for patients with Crohn's disease.
Amphetamine
go.drugbank.com/drugs/DB00182ApprovedIllicitInvestigationalAmphetamine structure presents one chiral center and it exists in the form of dextro- and levo-isomers.[A18540] The first product of Smith, Kline and French was approved by the FDA on 1976. … It was previously used for a large variety of conditions and this changed until this point where its use is highly restricted.
Categories: Psychostimulants, Agents Used for ADHD and NootropicsCinchocaine
go.drugbank.com/drugs/DB00527ApprovedVet approved(From Martindale, The Extra Pharmacopoeia, 30th ed, p1006) … A local anesthetic of the amide type now generally used for surface anesthesia.
Mixtures: Scheriproct - SalbeCategories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Anesthetics for Topical UseVosoritide
go.drugbank.com/drugs/DB11928ApprovedInvestigational[L39229] It was approved for use under the brand name Voxzogo (BioMarin Pharmaceutical Inc.) in the EU in August 2021 and the US in November 2021,[L39245,L39241] becoming the first pharmacological intervention … [A242277] It results from a gain-of-function missense mutation in _FGFR3_ that results in a dramatic suppression of bone growth, both in volume and in length.
Categories: Drugs for Treatment of Bone DiseasesSarecycline
go.drugbank.com/drugs/DB12035ApprovedInvestigationalSarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 … Based upon data from Global Burden of Disease studies, the acne vulgaris condition affects up to 85% of young adults aged 12 to 25 years globally - with the possibility of permanent physical and mental
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UsemRNA-1283
go.drugbank.com/drugs/DB22668ApprovedInvestigational[L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from … previously approved COVID-19 mRNA vaccines, including the original [Moderna COVID-19 Vaccine], mRNA-1283 encodes only the immunodominant regions (NTD and RBD) of the SARS-CoV-2 spike protein, allowing for
Soft Tissue Sarcoma
go.drugbank.com/conditions/DBCOND0029966Synonyms: Sarcoma, no International Classification of Diseases for Oncology subtypeSquamous Cell Carcinoma In-situ (SCC-is)
go.drugbank.com/conditions/DBCOND0043487Drugs: Aminolevulinic acidSynonyms: Squamous cell carcinoma, no International Classification of Diseases for Oncology subtype, Squamous cell carcinoma in situ, no International Classification of Diseases for Oncology subtype